about
Novel Transthyretin Amyloid Fibril Formation Inhibitors: Synthesis, Biological Evaluation, and X-Ray Structural AnalysisX-ray crystal structure and activity of fluorenyl-based compounds as transthyretin fibrillogenesis inhibitorsN-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic ActivityA new crystal form of human transthyretin obtained with a curcumin derived ligandSynthesis and structural analysis of halogen substituted fibril formation inhibitors of Human Transthyretin (TTR)Sugar-Based Arylsulfonamide Carboxylates as Selective and Water-Soluble Matrix Metalloproteinase-12 InhibitorsSynthesis and evaluation of the pharmacological activity of rigid analogues of sympathomimetic catecholamines derived from bicyclo[2.2.1]heptaneSynthesis and antiviral properties of 9-[(2-methyleneaminoxyethoxy)methyl]guanine derivatives as novel Acyclovir analoguesSynthesis and dopaminergic properties of the two enantiomers of 3-(3,4-dimethylphenyl)-1-propylpiperidine, a potent and selective dopamine D4 receptor ligand.TTR fibril formation inhibitors: is there a SAR?Synthesis and antiangiogenic activity study of new hop chalcone Xanthohumol analogues.Selective arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models.Synthesis and preliminary evaluation in tumor bearing mice of new (18)F-labeled arylsulfone matrix metalloproteinase inhibitors as tracers for positron emission tomography.Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.Synthesis and in-vitro antitumour activity of new naphthyridine derivatives on human pancreatic cancer cells.New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2).Synthesis of heteroaromatic analogues of (2-aryl-1-cyclopentenyl-1-alkylidene)-(arylmethyloxy)amine COX-2 inhibitors: effects on the inhibitory activity of the replacement of the cyclopentene central core with pyrazole, thiophene or isoxazole ring.Aryl-substituted methyleneaminoxymethyl (MAOM) analogues of diarylcyclopentenyl cyclooxygenase-2 inhibitors: effects of some structural modifications on their biological properties.(E)-[2-(4-Methylsulphonylphenyl)-1-cyclopentenyl-1-methyliden](arylmethyloxy)amines. Methyleneaminoxymethyl (MAOM) analogues of diarylcyclopentenyl cyclooxygenase-2 inhibitors: synthesis and biological properties.Different binding modes of structurally diverse ligands for human D3DAR.Synthesis and inhibitory activity towards human leukocyte elastase of new 7alpha-methoxy and 7alpha-chloro (2-acyloxymethyl) cephem derivatives.Conformationally restrained analogues of sympathomimetic catecholamines. Synthesis and adrenergic activity of 5,6- and 6,7-dihydroxy-3,4-dihydrospiro[naphthalen-1(2H)-2',5'-morpholines].Spirotetrahydronaphthalene analogues of sympathomimetic catecholamines. Synthesis and adrenergic activity of 5,6- and 6,7-dihydroxy-3,4-dihydrospiro[naphthalen-1 (2H)-3'-piperidines].New N-n-propyl-substituted 3-aryl- and 3-cyclohexylpiperidines as partial agonists at the D4 dopamine receptor.Synthesis and prostaglandin synthase inhibitory activity of new aromatic O-alkyloxime ethers substituted with methylsulfonamido or methylsulfonyl groups on their aliphatic portion.Synthesis and COX-2 inhibitory properties of N-phenyl- and N-benzyl-substituted amides of 2-(4-methylsulfonylphenyl)cyclopent-1-ene-1-carboxylic acid and of their pyrazole, thiophene and isoxazole analogs.Synthesis and antimicrobial activity of new 7 beta-(benzo[a]dihydrocarbazolyloxyacetyl)-substituted cephalosporins.Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: synthesis and biological evaluation.A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs.Synthesis and 5-HT2A, 5-HT1A and alpha1-binding affinities of 2-[2-Hydroxy-3-(pyridin-3-yl-methyl)amino]-, 2-[2-hydroxy-3-(2-pyridin-2-yl-ethyl)amino]- and 2-[2-hydroxy-3-(4-N-methyl-piperazin-1-yl)-amino]propoxybenzaldehyde-O-(substituted) benzyl oTargeting Different Transthyretin Binding Sites with Unusual Natural Compounds.N-(Aroyl)-N-(arylmethyloxy)-α-alanines: Selective inhibitors of aldose reductase.Bifunctional Inhibitors as a New Tool To Reduce Cancer Cell Invasion by Impairing MMP-9 Homodimerization.A new D₂ dopamine receptor agonist allosterically modulates A(2A) adenosine receptor signalling by interacting with the A(2A)/D₂ receptor heteromer.Structural Insights on Carbonic Anhydrase Inhibitory Action, Isoform Selectivity, and Potency of Sulfonamides and Coumarins Incorporating Arylsulfonylureido GroupsDevelopment of Thioaryl-Based Matrix Metalloproteinase-12 Inhibitors with Alternative Zinc-Binding Groups: Synthesis, Potentiometric, NMR, and Crystallographic StudiesSynthesis and cycloxygenase inhibitory properties of new naphthalene-methylsulfonamido, naphthalene-methylsulfonyl and tetrahydronaphthalen-methylsulfonamido compoundsTricyclic Sulfonamides Incorporating Benzothiopyrano[4,3-c]pyrazole and Pyridothiopyrano[4,3-c]pyrazole Effectively Inhibit α- and β-Carbonic Anhydrase: X-ray Crystallography and Solution Investigations on 15 IsoformsSynthesis, molecular docking and binding studies of selective serotonin transporter inhibitorsDesign, Synthesis, Biological Evaluation, and NMR Studies of a New Series of Arylsulfones As Selective and Potent Matrix Metalloproteinase-12 Inhibitors
P50
Q27656578-94079673-A923-4D0B-A143-5DE64F507FC6Q27701718-4FA2DCA8-03A5-4B2F-8886-7DB28AC3B47CQ27701780-1F4B2050-9DEE-478E-901B-D6E437EA6A83Q27703670-40275E50-2D67-43FE-BF40-0DEB57F7B310Q27704552-0994A490-D364-45BA-9898-D90BBCA89D06Q27715081-E2EECF69-5704-4C68-A640-35CCCA186F6AQ28342404-F3C6DC80-6CE3-40E6-9AEC-715C8B365E4FQ28377690-691A95BB-807C-43D4-905C-492860DA4636Q32020751-B2ADB84A-E811-4FA9-ADC2-33383FAFAD1DQ37999494-0D249256-2301-4B09-BD27-1ED2BBDF1B11Q38650903-DF98FE9D-5E7A-432B-9911-42473956DE54Q39094755-B501E8A2-3574-45EB-9EFC-D480A8E874F0Q39185697-8007CE96-010F-4ABA-9AA8-6161A817C5CDQ39735845-73CCDB9A-260C-4A12-9C06-B96579EF1C16Q39808966-C738AEBA-6E23-490B-AA89-161CDE1A4D12Q40567576-54D1E324-8454-4EF4-85EA-2F829DA73EB5Q40666140-21E75C28-9FA3-4CFF-BAF0-40A49812F4BCQ40717222-16C41D0F-E032-4BDA-9053-CBA6A1F67A20Q40732431-3138D4F8-1B03-4F9F-8916-79DF2A0435DDQ42797215-379E5673-CDE3-426D-8663-FD7C3CC555F0Q43581203-923622A1-E03E-403C-BCBB-D33B068224FFQ43884074-BDFB7C3F-20B3-41D0-A43D-FC9779726772Q43989502-704D7C3E-0815-49DD-97E4-014BD1E9B23FQ44262355-30E7DFA4-3FC2-4EEC-889F-845AB10A35D1Q44588318-591B56B7-AD05-4198-B88E-F980B6CCE4EBQ44748141-2E8B87CC-8CBB-450D-A563-5E8613514862Q45036726-B31E0304-7C75-4879-9369-61491700F095Q45788712-B1678D7D-30B6-4D68-8FC1-CD778AEC77A1Q46443178-87140A1C-20FD-495A-BD7F-15DEA318539FQ48254798-9F147ACC-32EF-4745-B331-3C1465269214Q50855015-98F2679C-77BF-4F87-9589-93C673F38651Q51065769-E22296FA-1F11-4818-857C-2C643A0E9143Q51088787-1B887C46-3AE4-4593-9052-BE0DDD14F684Q51762192-F64DB4DE-7477-4D5E-BB5E-49F3B88CE571Q57909155-6A90E98E-7EA7-48B4-836A-32125D8BBCFAQ58308020-E5659A0F-05F9-418F-835C-E6D5922D8975Q58308093-12D62C2B-AB6C-43F7-A5D0-5E6D21B1027DQ58308152-4C9D55CC-40BA-4522-8098-8CCE7AFC2845Q58308174-56C6A838-0472-44DB-AC9F-1713CA466717Q58308192-344064C0-4B6D-46BA-8856-388EF075DEED
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Elisabetta Orlandini
@ast
Elisabetta Orlandini
@en
Elisabetta Orlandini
@es
Elisabetta Orlandini
@nl
type
label
Elisabetta Orlandini
@ast
Elisabetta Orlandini
@en
Elisabetta Orlandini
@es
Elisabetta Orlandini
@nl
altLabel
Elisabetta ORLANDINI
@en
Orlandini E.
@en
prefLabel
Elisabetta Orlandini
@ast
Elisabetta Orlandini
@en
Elisabetta Orlandini
@es
Elisabetta Orlandini
@nl
P106
P1153
7005564489
P21
P31
P496
0000-0003-3398-2787